Zevra Therapeutics share price logo

Zevra Therapeutics

NASDAQ: ZVRA

Small Cap

$11.88

+0.31

(+2.70%)

Live

as on

Zevra Therapeutics Stock Performance

as on August 20, 2026 at 3:10 am IST

  • Day's Low

    Day's High

    $11.73
    $11.99
    downward going graph

    1.26%

    Downside

    0.93%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $7.16
    $15.04
    downward going graph

    39.73%

    Downside

    26.56%

    Upside

    downward going graph

Zevra Therapeutics share price movements today

Previous Close
$11.57
Open
$11.84
Volume
282.1K
Market Cap
$672.2M
Day's Low - High
$11.73 - $11.99
52 Week Low - High
$7.16 - $15.04

Zevra Therapeutics Historical Returns

1 Month Return
-11.35 %
3 Month Return
+ 2.82 %
1 Year Return
+ 20.04 %
3 Year Return
+ 129.15 %
5 Year Return
0 %

Zevra Therapeutics Stock Fundamentals & Key Indicators

Check Zevra Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$672.2M

EPS (TTM)

0.9603

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.88%

PE Ratio (TTM)

11.64

Industry PE ratio

-7.283372093023256

PEG Ratio

0.006176001206599302

EBITDA

73.0M

Revenue (TTM)

136.1M

Profit Margin

94.96%

Return On Equity TTM

32.77%

Zevra Therapeutics Stock Valuation

Track how Zevra Therapeutics P/E has moved over time to understand its valuation trends.

Zevra Therapeutics in the last 5 years

  • Overview

  • Trends

Lowest (-30.31x)

December 31, 2021

Industry (-7.28x)

December 31, 2025

Today (6.40x)

December 31, 2025

Highest (6.40x)

December 31, 2025

LowHigh

Today’s Price to Earnings Ratio: 6.40x

Zevra Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Zevra Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Zevra Therapeutics image
Zevra Therapeutics
BUY$672.2MNA11.6494.96%NA
Revolution Medicines image
Revolution Medicines
BUY$43.7B669.3%NA0.00%NA
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
BUY$128.2B154.86%29.8286.04%NA
Regeneron image
Regeneron
BUY$82.7B24.1%19.2484.86%0.44999999999999996%

Stock Returns calculator for Zevra Therapeutics Stock including INR - Dollar returns

The Zevra Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

Zevra Therapeutics investment value today

Current value as on today

₹1,38,530

Returns

₹38,530

(+38.53%)

Returns from Zevra Therapeutics Stock

₹25,981 (+25.98%)

Dollar Impact

₹12,549 (+12.55%)

Analyst Recommendation on Zevra Therapeutics Stock

Based on 9 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 9 analysts, 100% of analysts recommend a 'BUY' rating for Zevra Therapeutics. Average target price of $25

Zevra Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Zevra Therapeutics.

What analysts predicted

52.48%UPSIDE

Target Price

$25

Current Price

$11.88

Analyzed by

9 Analysts

Target

$25.00

Zevra Therapeutics target price $25, a slight upside of 52.48% compared to current price of $11.88. According to 9 analysts rating.

Indian Investors' Interest in Zevra Therapeutics Stock

Search interest for Zevra Therapeutics Stock has decreased by -25% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-25% versus previous 30 day period

Zevra Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
3
4
3
12
20
25
26
34
36
39
Gross Profit
0
0
1
10
19
13
24
32
33
38
Operating Income
-20
-23
-27
-15
-5
-71
4
9
8
16
EBITDA
-14
-16
-29
-16
1
80
1
14
43
13
Interest Expense
0
2
2
2
1
2
2
1
1
-
Depreciation
1
1
1
1
1
1
0
0
0
0
Income Before Tax
-16
-19
-33
-20
-1
76
0
12
44
12
Income Tax Expense
0
0
-
15
1
2
0
0
6
4
Net Income
-16
-19
-33
-35
-3
74
0
12
37
8
Net Profit Margin
4.67%
19.69%
37.67%
88.66%
93.41%
52.17%
94.04%
95.55%
93.75%
96.16%

Zevra Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
12
13
28
10
27
23
106
Gross Profit
0
0
9
11
26
9
24
16
89
Operating Income
-33
-55
-20
-5
7
-42
-49
-87
-4
EBITDA
-33
-53
-17
-5
-7
-25
-43
-76
98
Interest Expense
7
7
6
7
0
0
1
7
7
Depreciation
0
0
0
0
0
0
1
6
4
Income Before Tax
-43
-56
-24
-12
-8
-26
-46
-90
86
Income Tax Expense
0
0
0
0
0
0
-
15
3
Net Income
-43
-56
-24
-12
-8
-26
-46
-105
83
Net Profit Margin
0.00%
0.00%
77.06%
90.18%
92.81%
97.82%
89.28%
68.59%
84.52%

Zevra Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-16
-19
-33
-35
-3
74
0
12
36
10
Operating Cash Flow
-16
-19
-18
-16
-8
-3
4
5
6
17
Investing Cash Flow
14
0
-31
-5
10
11
-4
0
79
31
Financing Cash Flow
1
15
64
0
1
1
6
2
-52
1
Change in Cash
0
-3
14
-20
3
10
6
7
33
49

Zevra Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-43
-56
-24
-12
-8
-26
-46
-105
83
Operating Cash Flow
-33
-54
-23
-1
10
-18
-33
-69
-1
Investing Cash Flow
27
33
3
0
-15
-36
-17
-22
18
Financing Cash Flow
0
28
4
2
113
8
28
82
12
Change in Cash
-5
7
-15
0
108
-46
-22
-9
28

Mutual Funds that own Zevra Therapeutics Stock

Check out the Mutual Funds with significant holdings in Zevra Therapeutics.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
4.057436%
2409459
Fidelity Contrafund
3.834449%
2277041
Fidelity Salem Street Trust
1.012778%
601426
Fidelity Concord Street Trust
0.955766%
567570
VANGUARD SCOTTSDALE FUNDS
0.559354%
332166
See all

Global Institutional Holdings in Zevra Therapeutics

Funds
Holdings
Michael Rockefeller
5.81%
Vanguard
5.31%
iShares
4.82%
Chuck Royce
1.66%
SPDR
1.14%
See all

Zevra Therapeutics News & Key Events

  • img

    Today's Timeline - 10 March

    Tue, 02:12 PM

    -

    Zevra Therapeutics reports earnings of 19 cents, beating estimates, with sales of $34.1 million, boosting shares by 17.2%.

Insights on Zevra Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 8 quarters, 3.69M → 39.66M (in $), with an average increase of 24.3% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Revolution Medicines, Inc. Common Stock has given 491.1% return, outperforming this stock by 462.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 629.2% return, outperforming this stock by 496.9%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 month, ZVRA stock has moved down by -9.4%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 37.89M → 8.75M (in $), with an average decrease of 76.9% per quarter

About Zevra Therapeutics

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.
OrganisationZevra Therapeutics
Headquarters101 Federal Street, Boston, MA, United States, 02110
IndustryBiotechnology
CEOMr. Neil F. McFarlane
E-voting on sharesClick here to vote

Key Management of Zevra Therapeutics

Name

Title

Dr. Christopher M. Lauderback Ph.D.

Senior Vice President of Manufacturing

Mr. Joshua M. Schafer M.B.A., M.S.

Chief Commercial Officer

Ms. Tanya Hayden

Senior VP & Chief of Staff

Mr. Rahsaan W. Thompson J.D.

Chief Legal Officer, Secretary & Compliance Officer

Mr. Justin A. Renz CPA, MBA

CFO & Treasurer

Ms. Alison Peters

Chief People Officer

Mr. Gerald J. Orehostky

Senior Vice President of Regulatory Affairs & Quality

Mr. Neil F. McFarlane

President, CEO & Director

Ms. Nichol L. Ochsner

Vice President of Investor Relations & Corporate Communications

Dr. Adrian Quartel FFPM, M.D.

Consultant

FAQs

What is Zevra Therapeutics share price today?

Zevra Therapeutics share price today is $11.88 as on . Zevra Therapeutics share today touched a day high of $11.99 and a low of $11.73.

What is the 52 week high and 52 week low for Zevra Therapeutics share?

Zevra Therapeutics share touched a 52 week high of $15.04 on and a 52 week low of $7.16 on . Zevra Therapeutics stock price today i.e. is trending at $11.88,which is 20.98% down from its 52 week high and 65.92% up from its 52 week low.

What is Zevra Therapeutics's market capitalisation today?

Zevra Therapeutics market capitalisation is $0.00T as on .

How to invest in Zevra Therapeutics Stock (ZVRA) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Zevra Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Zevra Therapeutics Shares that will get you 0.1263 shares as per Zevra Therapeutics share price of $11.88 per share as on August 19, 2026 at 9:40 pm IST.

What is the minimum amount required to buy Zevra Therapeutics Stock (ZVRA) from India?

Indian investors can start investing in Zevra Therapeutics (ZVRA) shares with as little as ₹95.743 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹957.43 in Zevra Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Zevra Therapeutics share’s latest price of $11.88 as on August 19, 2026 at 9:40 pm IST, you will get 0.8418 shares of Zevra Therapeutics. Learn more about fractional shares .